Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciencs Announces Agreement for Evaluation of L-glutamine for Pancreatic CancerAugust 31, 2026

Emmaus announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC). The results of the GlutaPanc trial (NCT04634539), recently published in Nature Cancer.

Emmaus Life Sciences Reports Quarterly Financial ResultsAugust 14, 2026

Emmaus Life Sciences reports financial and operational results for the three and six months ended June 30, 2026.

Emmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2026

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026.

Emmaus Life Sciences Reports 2025 Financial ResultsMarch 31, 2026

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year ended December 31, 2025.

Emmaus Life Sciences Announces Strategic TransactionDecember 30, 2025

Enters into North American License and Exclusive Distribution Agreement